Non-Muscle invasive Bladder Cancer ("NMIBC")
Heat Biologics has developed an ImPACT-based treatment for patients with NMIBC. Similar to HS-110, HS-410 was designed based on knowledge of the various antigens that are known to be shared amongst a high proportion of patients with bladder cancer. Heat is currently conducting a Phase 2 trial using HS-410 for the treatment of NMIBC. This trial is being performed either in combination with the standard of care, BCG therapy, or alone. Heat believes that BCG is likely to synergize with HS-410 due to the activity of BCG to promote trafficking of HS-410 activated cytotoxic T cells into the bladder endothelium. On the other hand, monotherapy HS-410 has significant patient administration advantages by avoiding intravesical delivery, thus evaluation of its single-agent activity is warranted.
For more information please reference study protocol NCT02010203 on clinicaltrials.gov.
About Non-Muscle Invasive Bladder Cancer
In 2015, the American Cancer Society estimated 74,000 new cases of bladder cancer will be diagnosed in the U.S. and an estimated 16,000 deaths will occur. More than 500,000 people in the U.S. have been treated for bladder cancer and 70% of those patients have non-muscle invasive bladder cancer. Importantly, the U.S. Food and Drug Administration has not approved any new drugs to treat bladder cancer in more than 25 years. Heat's HS-410 represents a viable opportunity to address a significant unmet medical need.
